Compare DRIO & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRIO | ELUT |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.8M | 42.5M |
| IPO Year | 2013 | 2020 |
| Metric | DRIO | ELUT |
|---|---|---|
| Price | $6.82 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $35.00 | $6.00 |
| AVG Volume (30 Days) | 19.5K | ★ 54.0K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1559.02 | 146.77 |
| EPS | ★ 1.75 | N/A |
| Revenue | $7,394,000.00 | ★ $12,293,000.00 |
| Revenue This Year | $20.27 | N/A |
| Revenue Next Year | $47.58 | $10.83 |
| P/E Ratio | $4.02 | ★ N/A |
| Revenue Growth | ★ 43.02 | N/A |
| 52 Week Low | $5.84 | $0.50 |
| 52 Week High | $17.74 | $1.39 |
| Indicator | DRIO | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 40.40 |
| Support Level | $6.18 | $0.51 |
| Resistance Level | $8.10 | $1.04 |
| Average True Range (ATR) | 0.60 | 0.08 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 29.19 | 7.93 |
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.